ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
InnoCare Presents Latest Clinical Data of Orelabrutinib at the16th International Conference on MPresents Latest Clinical Data of Orelabrutinib at the16th International Conference on Malignant Lymphoma
June 18, 2021InnoCare announced today the company presented the latest clinical data of the Bruton's tyrosine kinase (BTK) inhibitor orelabrutinib at the 16th International Conference on Malignant Lymphoma (ICML). -
Innocare Gets Approval from NMPA for Orelabrutinib
January 08, 2021Innocare has received approval by the National Medical Products Administration of China (NMPA) for Orelabrutinib, an orally available potent BTK inhibitor that irreversibly binds to BTK to induce downstream kinase inactivation and cell death.
Pharma Sources Insight January 2025
